Literature DB >> 12470181

X-linked bulbospinal neuronopathy: Kennedy disease.

Anne D Sperfeld1, Jochem Karitzky, Dagmar Brummer, Herbert Schreiber, Jürgen Häussler, Albert C Ludolph, C Oliver Hanemann.   

Abstract

OBJECTIVE: To characterize the earliest symptoms of X-linked bulbospinal neuronopathy (Kennedy disease [KD]) during the course of the disease, including a definition of the age of onset.
METHODS: We describe the earliest symptoms, signs on clinical investigation, electrophysiological and muscle biopsy specimen findings, and creatine kinase levels in 34 patients with KD. Correlations were made among the CAG-repeat length and clinical symptoms, age at onset, and the presence of electrophysiological and laboratory findings.
RESULTS: Our findings indicate that the age at onset of KD is in adolescence which is earlier than previously thought. Most frequently early symptoms are gynecomastia, muscle pain, and premature muscular exhaustion. Weakness is not a typical initial symptom and is frequently found in distal limbs if present early. We found a correlation between the of number of CAG repeats and the age at onset of weakness but not to the age at onset of KD. Furthermore, no correlations were found between the occurrence of gynecomastia, tremor, increased creatine kinase levels, and additional myopathic changes in muscle biopsy specimens.
CONCLUSIONS: Our data show that KD is a multisystem disorder with onset in adolescence. Because of the heterogeneity of clinical presentation and no correlation between the number of CAG repeats and most of the clinical hallmarks of KD, we suggest that other environmental or genetic factors contribute to the manifestation of specific organ systems in KD.

Entities:  

Mesh:

Year:  2002        PMID: 12470181     DOI: 10.1001/archneur.59.12.1921

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  39 in total

Review 1.  Polyglutamine toxicity in non-neuronal cells.

Authors:  Jennifer W Bradford; Shihua Li; Xiao-Jiang Li
Journal:  Cell Res       Date:  2010-03-16       Impact factor: 25.617

2.  Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy.

Authors:  Atsushi Hashizume; Masahisa Katsuno; Haruhiko Banno; Keisuke Suzuki; Noriaki Suga; Fumiaki Tanaka; Gen Sobue
Journal:  J Neurol       Date:  2011-09-28       Impact factor: 4.849

Review 3.  Onset Manifestations of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease).

Authors:  Josef Finsterer; Gianni Soraru
Journal:  J Mol Neurosci       Date:  2015-10-19       Impact factor: 3.444

4.  Whole brain-based analysis of regional white matter tract alterations in rare motor neuron diseases by diffusion tensor imaging.

Authors:  Alexander Unrath; Hans-Peter Müller; Axel Riecker; Albert C Ludolph; Anne-Dorte Sperfeld; Jan Kassubek
Journal:  Hum Brain Mapp       Date:  2010-11       Impact factor: 5.038

5.  Frontotemporal cognitive function in X-linked spinal and bulbar muscular atrophy (SBMA): a controlled neuropsychological study of 20 patients.

Authors:  Georg Rüdiger Soukup; Anne-Dorte Sperfeld; Ingo Uttner; Jochen Karitzky; Albert Christian Ludolph; Jan Kassubek; Herbert Schreiber
Journal:  J Neurol       Date:  2009-07-02       Impact factor: 4.849

6.  [Motor neuron diseases].

Authors:  S Petri; T Meyer
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

Review 7.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

8.  A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study.

Authors:  Atsushi Hashizume; Masahisa Katsuno; Keisuke Suzuki; Haruhiko Banno; Noriaki Suga; Tomoo Mano; Amane Araki; Yasuhiro Hijikata; Christopher Grunseich; Angela Kokkinis; Akihiro Hirakawa; Hirohisa Watanabe; Masahiko Yamamoto; Kenneth H Fischbeck; Gen Sobue
Journal:  Neuromuscul Disord       Date:  2015-03-20       Impact factor: 4.296

Review 9.  Diagnostic Clinical, Electrodiagnostic and Muscle Pathology Features of Spinal and Bulbar Muscular Atrophy.

Authors:  Manu E Jokela; Bjarne Udd
Journal:  J Mol Neurosci       Date:  2015-11-16       Impact factor: 3.444

10.  CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model.

Authors:  Hiroaki Adachi; Masahiro Waza; Keisuke Tokui; Masahisa Katsuno; Makoto Minamiyama; Fumiaki Tanaka; Manabu Doyu; Gen Sobue
Journal:  J Neurosci       Date:  2007-05-09       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.